Stockscreener 앱 받기
0.89
0.18%
0.0016
전일 마감가:
$0.8884
열려 있는:
$0.92
하루 거래량:
97,821
Relative Volume:
0.22
시가총액:
$59.25M
수익:
-
순이익/손실:
$-46.12M
주가수익비율:
-1.0299
EPS:
-0.8642
순현금흐름:
$-41.02M
1주 성능:
+1.83%
1개월 성능:
+10.92%
6개월 성능:
-64.40%
1년 성능:
-35.51%
1일 변동 폭
$0.8605
$0.9242
1주일 범위
$0.836
$0.95
52주 변동 폭
$0.7113
$2.815
Inflarx N V Stock (IFRX) Company Profile
IFRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IFRX
Inflarx N V
|
0.8826 | 58.26M | 0 | -46.12M | -41.02M | -0.8642 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.62 | 118.67B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.09 | 59.23B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
420.52 | 52.67B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
692.94 | 41.24B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
309.17 | 32.36B | 3.81B | -644.79M | -669.77M | -6.24 |
Inflarx N V Stock (IFRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-29 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-04-05 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-02-28 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-10-28 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2021-03-11 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-06 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-10-08 | 개시 | H.C. Wainwright | Buy |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2020-04-30 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2019-06-05 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2019-06-05 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-05 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2019-06-05 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-06-05 | 다운그레이드 | SunTrust | Buy → Hold |
| 2019-01-29 | 개시 | Robert W. Baird | Outperform |
| 2018-12-10 | 개시 | Credit Suisse | Outperform |
| 2018-07-13 | 개시 | BMO Capital Markets | Outperform |
| 2018-06-28 | 개시 | Raymond James | Outperform |
| 2018-06-28 | 개시 | SunTrust | Buy |
| 2018-02-08 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
Inflarx N V 주식(IFRX)의 최신 뉴스
Sentiment analysis tools applied to InflaRx N.V.Real Time Alert System for Market Moves - Newser
Is it time to cut losses on InflaRx N.V.Free Watchlist for Smart Swing Trading - Newser
Understanding InflaRx N.V.’s price movementRapid Trade Forecast Based on Indicators - Newser
How high can InflaRx N.V. stock goVolume Confirmed Setup with Entry Confidence - Newser
Tools to assess InflaRx N.V.’s risk profileFree Profit Target Stock Opportunity Monitor - Newser
What to do if you’re stuck in InflaRx N.V.Free Swing Trading Plan With Smart Signals - Newser
Applying chart zones and confluence areas to InflaRx N.V.Real Time Screener for Growth Trades - Newser
Sector ETF performance correlation with InflaRx N.V.Buy/Sell Zone Confirmation Technical Analysis - Newser
What MACD signals say about InflaRx N.V.Free Beginner Friendly Stock Selection Guide - Newser
What are analysts’ price targets for InflaRx N.V. in the next 12 monthsUnlock powerful portfolio management tools - Jammu Links News
How does InflaRx N.V. compare to its industry peersMaximize portfolio returns with smart trading - Jammu Links News
What drives InflaRx N.V. stock priceFree Stock Market Return Analysis - Jammu Links News
Should I hold or sell InflaRx N.V. stock in 2025Invest smarter with expert trading signals - Jammu Links News
What is InflaRx N.V. company’s growth strategyTransform your portfolio with high-yield stocks - Jammu Links News
What are the latest earnings results for InflaRx N.V.Consistent high-performance stocks - Jammu Links News
Key resistance and support levels for InflaRx N.V.Free Fundamental Winners With Safe Entry Plan - Newser
Applying Elliott Wave Theory to InflaRx N.V.Free Scalable Portfolio Growth Suggestions - Newser
How does InflaRx N.V. generate profit in a changing economyConsistently superior profits - Jammu Links News
How many analysts rate InflaRx N.V. as a “Buy”Exceptional ROI - Jammu Links News
When is InflaRx N.V. stock expected to show significant growthMaximize portfolio returns with smart trading - Jammu Links News
Is InflaRx N.V. Stock a Good Fit for Conservative InvestorsEarnings Based Stock Performance Forecast - Newser
InflaRx (IFRX) to Release Earnings on Thursday - Defense World
Why InflaRx N.V. stock attracts strong analyst attentionGrowth Projection Summary for Long-Term Investors - Newser
How volatile is InflaRx N.V. stock compared to the marketBeginner Investor Report With Low Risk - Jammu Links News
Sentiment Turns Positive on InflaRx N.V. — Reversal AheadLong Hold Safe Return Strategy Reviewed - metal.it
InflaRx N.V. stock momentum explainedFree Low Risk Buy Zone Opportunity Watch - Newser
Does InflaRx N.V. stock perform well during market downturnsReal Time Tracker With High Returns - Jammu Links News
InflaRx receives Nasdaq notice for non-compliance with minimum bid price rule - MSN
InflaRx (NASDAQ:IFRX) Trading 2.8% Higher – What’s Next? - Defense World
InflaRx to Report Second Quarter 2025 Results on August 7, 2025 - GlobeNewswire
InflaRx Q2 Earnings Coming August 7: Anti-Inflammatory Drug Developer's Latest Financial Picture - Stock Titan
Top Risks to Consider Before Buying InflaRx N.V. Stock7-Day Equity Return Range Forecast Model - Newser
What makes InflaRx N.V. stock price move sharplyBreakout Stock Opportunities with Low Drawdown - Newser
Inflarx N V (IFRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.36%
1.05%
자본화:
|
볼륨(24시간):